RT Journal Article
T1 IgM-enriched immunoglobulin improves colistin efficacy in a pneumonia model by Pseudomonas aeruginosa.
A1 Cebrero-Cangueiro, Tania
A1 Labrador-Herrera, Gema
A1 Carretero-Ledesma, Marta
A1 Herrera-Espejo, Soraya
A1 Álvarez-Marín, Rocío
A1 Pachón, Jerónimo
A1 Cisneros, José Miguel
A1 Pachón-Ibáñez, María Eugenia
AB We evaluated the efficacy of ceftazidime or colistin in combination with polyclonal IgM-enriched immunoglobulin (IgM-IG), in an experimental pneumonia model (C57BL/6J male mice) using two multidrug-resistant Pseudomonas aeruginosa strains, both ceftazidime-susceptible and one colistin-resistant. Pharmacodynamically optimised antimicrobials were administered for 72 h, and intravenous IgM-IG was given as a single dose. Bacterial tissues count and the mortality were analysed. Ceftazidime was more effective than colistin for both strains. In mice infected with the colistin-susceptible strain, ceftazidime reduced the bacterial concentration in the lungs and blood (-2.42 and -3.87 log10 CFU/ml) compared with colistin (-0.55 and -1.23 log10 CFU/ml, respectively) and with the controls. Colistin plus IgM-IG reduced the bacterial lung concentrations of both colistin-susceptible and resistant strains (-2.91 and -1.73 log10 CFU/g, respectively) and the bacteraemia rate of the colistin-resistant strain (-44%). These results suggest that IgM-IG might be useful as an adjuvant to colistin in the treatment of pneumonia caused by multidrug-resistant P. aeruginosa.
YR 2022
FD 2022-06-21
LK http://hdl.handle.net/10668/21801
UL http://hdl.handle.net/10668/21801
LA en
DS RISalud
RD Apr 8, 2025